Cingulate (NASDAQ:CING) Price Target Raised to $20.00

Cingulate (NASDAQ:CING) had its price target hoisted by HC Wainwright from $8.00 to $20.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Cingulate’s FY2025 earnings at ($2.97) EPS.

A number of other equities analysts have also weighed in on CING. Roth Capital raised shares of Cingulate to a “strong-buy” rating in a research report on Friday, January 10th. Roth Mkm assumed coverage on Cingulate in a research report on Friday, January 10th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Maxim Group upgraded Cingulate from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th.

Cingulate Stock Performance

Cingulate stock opened at $4.55 on Thursday. Cingulate has a 52 week low of $1.80 and a 52 week high of $58.32. The firm’s 50-day simple moving average is $4.58 and its 200 day simple moving average is $4.56.

Cingulate (NASDAQ:CING) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($2.22) by $0.39. As a group, sell-side analysts predict that Cingulate will post -11.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cingulate stock. Jane Street Group LLC purchased a new position in Cingulate Inc. (NASDAQ:CING) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 21,031 shares of the company’s stock, valued at approximately $106,000. Jane Street Group LLC owned 0.66% of Cingulate as of its most recent SEC filing. 41.31% of the stock is owned by hedge funds and other institutional investors.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.